Share on StockTwits

Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Aryeh sold 40,320 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.44, for a total transaction of $3,082,060.80. Following the transaction, the director now directly owns 31,243 shares of the company’s stock, valued at approximately $2,388,215. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Ligand Pharmaceuticals (NASDAQ:LGND) traded down 2.82% during mid-day trading on Friday, hitting $76.92. The stock had a trading volume of 553,171 shares. Ligand Pharmaceuticals has a 52 week low of $20.21 and a 52 week high of $80.42. The stock has a 50-day moving average of $61.02 and a 200-day moving average of $52.17. The company has a market cap of $1.570 billion and a price-to-earnings ratio of 152.50.

Ligand Pharmaceuticals (NASDAQ:LGND) last announced its earnings results on Tuesday, February 11th. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.19 by $0.16. The company had revenue of $14.70 million for the quarter, compared to the consensus estimate of $13.72 million. The company’s quarterly revenue was up 8.1% on a year-over-year basis. Analysts expect that Ligand Pharmaceuticals will post $1.31 EPS for the current fiscal year.

A number of analysts have recently weighed in on LGND shares. Analysts at TheStreet upgraded shares of Ligand Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Separately, analysts at Roth Capital raised their price target on shares of Ligand Pharmaceuticals from $69.00 to $92.00 in a research note on Wednesday. They now have a “positive” rating on the stock. Finally, analysts at MLV Capital raised their price target on shares of Ligand Pharmaceuticals to $82.00 in a research note on Monday. They now have a “buy” rating on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $67.07.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.